InflaRx to Present at Annual SVB Leerink Global Health Conference
InflaRx N.V. (Nasdaq: IFRX) will present at the 11th Annual SVB Leerink Healthcare Conference, scheduled for February 14-18, 2022. CFO Thomas Taapken and Chief Strategy Officer Jordan Zwick will engage in a fireside chat on February 17 at 10:40 am EST. The event will be accessible via a live audio webcast on the InflaRx website. InflaRx focuses on targeting the complement system to develop anti-inflammatory therapeutics, specializing in C5a and C5aR inhibitors for various autoimmune diseases.
- None.
- None.
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 11th Annual SVB Leerink Healthcare Conference being held virtually February 14-18, 2022.
Thomas Taapken, Chief Financial Officer of InflaRx, and Jordan Zwick, Chief Strategy Officer, will participate in a fireside chat moderated by an SVB Leerink research analyst on Thursday, February 17th at 10:40 am EST (4:40 pm CET). A live audio webcast of the presentation will be provided on the InflaRx website in the Investors section under Events & Presentations.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a and C5aR. Complement C5a and C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
Contacts:
InflaRx N.V.
Jordan Zwick – Chief Strategy Officer
Jason Stewart – Strategy & Investor Relations
Email: IR@inflarx.de
Tel: +1 917-338-6523
MC Services AG
Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks, uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
What is the date of InflaRx's presentation at the SVB Leerink Healthcare Conference?
Who will represent InflaRx at the conference?
What time will InflaRx’s fireside chat take place?
Where can I watch the InflaRx presentation?
What does InflaRx specialize in?
